AMF. Promis Neurosciences

ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference

ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
EN
13/10/2020

Underlying

AMF.Promis Neurosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Promis Neurosciences

 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Pers...

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ET CAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), as well...

June 17, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces First Quarter 2025 Financial Results First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis...

May 12, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Re...

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived An...

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines...

March 24, 2025 1 EN
 PRESS RELEASE
Free
AMF. Promis Neurosci...

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Va...

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that the Company will ...

March 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch